Prognostic impact of variants of uncertain significance (VUS) in BRCA genes and homologous recombination repair (HRR) genes in prostate cancer: a real-world multicenter study

This publication has 33 references indexed in Scilit:

• BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes
  Annals of Oncology, 2025
• Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience
  European Urology Oncology, 2025
• Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease
  European Urology Oncology, 2024
• Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study
  European Urology Oncology, 2024
• Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
  Annals of Oncology, 2024
• Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study
  European Urology Open Science, 2024
• SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP)
  Virchows Archiv, 2023
• Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis
  Medical Oncology, 2022
• Integrative Clinical Genomics of Advanced Prostate Cancer
  Cell, 2015
• Functional Assays for Analysis of Variants of Uncertain Significance inBRCA2
  Human Mutation, 2013